Rigel Pharmaceuticals Stock (NASDAQ: RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock

Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals Inc

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $20 to $24.

News

Price Target

Analyst Ratings

RIGL

B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $24

The three major indices were mostly flat in midday trading Wednesday with the S&amp;P 500 and Nasdaq slightly under the flatline and the Dow Jones<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44143660/howard-lutnick-says-president-definitely-thinks-theres-a-bitcoin-strategic-reserve"> up 39 points.&nbsp;</a>
Wall Street digested mixed economic data after the ISM Services PMI<a href="https://www.benzinga.com/news/econ-s/25/03/44143666/us-services-sector-unexpectedly-expands-in-february-despite-slowing-job-growth"> price index indicated</a> strong growth in the services sector, but the ADP employment report came in well below forecasts and added the fewest jobs in seven months. 
Traders awaited further <a href="https://www.benzinga.com/news/25/03/44143647/trump-considering-tariff-relief-for-mexico-canada-commerce-secretary-lutnick-says">developments on trade policy</a> after Commerce Secretary Howard Lutnick appeared on Bloomberg Television on Wednesday. Lutnick said President Donald Trump would likely make a decision on possible tariff relief for Mexico and Canada Wednesday afternoon.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a>
The yield on the 10-year US Treasury note was at 4.23% on Wednesday, trimming declines from the morning after expansion in the services sector, reflected by the ISM PMI easing concerns on lower growth. However, yields remained near four-month lows touched earlier in the week.  The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.24%.  
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was up 1% on Wednesday, and up nearly 5% on the week, as investors look forward to President Trump's White House crypto summit on Friday.&nbsp;
<h2 class="wp-block-heading">Wednesday's Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,207.74</td>
<td>-0.43%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,756.29</td>
<td>-0.38%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,470.06</td>
<td>-0.12%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,075.09</td>
<td>-0.21%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.43% at $574.36. </li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.14% at $424.98. </li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.58% to $492.67. </li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)&nbsp;slid 0.59% to $205.22. </li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)&nbsp;was down 0.19% to $207.85. </li>
<li>The&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)&nbsp;was down 3.31% to $84.09. </li>
</ul>
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers:&nbsp;</h2>
Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) shares plunged Wednesday after the company&#8217;s weak outlook overshadowed its <a href="https://www.benzinga.com/news/earnings/25/03/44142510/abercrombie-q4-earnings-beat-overshadowed-by-cautious-q1-outlook-stock-plunges">better-than-expected</a> fourth-quarter results. The company said it expects first-quarter EPS in the range of $1.25 to $1.45 versus the $2.01 estimate.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>ChargePoint Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) <a href="https://www.benzinga.com/quote/chpt" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/quote/chpt" target="_blank" rel="noreferrer noopener"></a></li>
<li>Ross Stores, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) </li>
<li>Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) </li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) &nbsp;</li>
<li>Box, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) </li>
<li>Sociedad Quimica y Minera S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) </li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) </li>
<li>Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>)</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) </li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) </li>
</ul>
Companies reporting after Wednesday&#8217;s closing bell include:&nbsp;
<ul>
<li>Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) </li>
<li>LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) </li>
<li>MongoDB, Inc. (NAS+DAQ:MDB) </li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) </li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) </li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) </li>
<li>Victorias Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) </li>
<li>Fortuna Mining Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) </li>
</ul>
Read Next:<a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying" target="_blank" rel="noreferrer noopener">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying" target="_blank" rel="noreferrer noopener">Markets Tank After Trump Confirms More Tariffs: Here's What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Market Summary

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Politics

Global

Markets

Movers

Tech

ETFs

General

$BTC

ARBE

AVAV

CHPT

CRWD

SPDR Dow Jones Industrial Average ETF Trust

GRND

MRVL

RGTI

ROST

STEM

iShares Trust Barclays 20+ Year Treasury Bond Fund

TREE

VSCO

Select Sector SPDR-Consumer Discretionary

Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday?

WIIM

Rigel Pharmaceuticals shares are trading lower. The company reported Q4 financial results.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $57 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) affirms FY2025 sales outlook from $200.00 million-$210.00 million to $200.00 million-$210.00 million vs $200.70 million estimate.

Guidance

Rigel Pharmaceuticals Affirms FY2025 revenue Guidance of $200.00M-$210.00M vs $200.70M Est

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.47 by 70.21 percent. This is a 1900 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $57.60 million which beat the analyst consensus estimate of $51.73 million by 11.34 percent. This is a 60.92 percent increase over sales of $35.79 million the same period last year.

Earnings

Earnings Beats

Rigel Pharmaceuticals Q4 EPS $0.80 Beats $0.47 Estimate, Sales $57.60M Beat $51.73M Estimate

U.S. stocks plunged Tuesday as President Donald Trump&#8216;s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44110685/markets-see-hardly-a-flesh-wound-so-far-but-centurys-biggest-trade-war-looms-says-bob-elliott">global trade tensions.</a>
The Dow Jones Industrial Average fell 1.8%, extending Monday&#8217;s sharp decline of nearly 650 points and heading towards its worst performance of 2025. The S&amp;P 500 decreased by 1.7%, while the Nasdaq Composite dropped 1.9%, putting it<a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44108913/tariffs-trump-tumult-how-to-trade-this-volatility-vix-surge"> on course</a> to enter correction territory, defined as a 10% drop from its recent peak.&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a>
<a href="https://www.benzinga.com/25/03/44102599/canadian-pm-justin-trudeau-retaliates-with-25-tariffs-on-us-goods-amid-escalating-trade-war">Affected countries</a> announced retaliatory measures, further dampening investor sentiment.
China announced retaliatory tariffs of up to 15% on certain U.S. products, including chicken, wheat, corn, and cotton. Canadian Prime Minister Justin Trudeau declared that Canada would impose a 25% tariff on U.S. goods. Mexican President Claudia Sheinbaum stated that Mexico would respond with tariffs and other measures, to be announced on Sunday.
The yield on the US 10-year Treasury note fell to 4.13% on Tuesday, its lowest level since October 2024. Markets are now pricing in three quarter-point rate cuts by the Federal Reserve in 2025, according to data from CME FedWatch. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) slipped 0.58%. 
Natural gas futures rose more than 8% on Tuesday, above $4.45/MMBtu, the highest since December 2022. Stockpiles remain below the five-year average due to earlier extreme cold in the U.S. while LNG export flows have reached record levels. The United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) ETF climbed 8.5%.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continued Monday's decline to trade below the $84,000 mark, leading crypto markets lower. 
<h2 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,175.89</td>
<td>-0.99%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,772.73</td>
<td>-1.32%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,535.92</td>
<td>-1.52%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,064.42</td>
<td>-1.81%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 1.24% to $576.36. </li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 1.45% at $425.81.&nbsp;</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.8% to $493.08.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) slid 1.1% to $205.00.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) was down 2.17% to $207.38.&nbsp;</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) was down 1.06% to $86.87.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Tuesday's Stock Movers:&nbsp;</h2>
Shares of Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), bucked the market trend, surging 18% after the company reported&nbsp;better-than-expected <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/03/44108947/okta-stock-is-surging-tuesday-heres-why">financial results</a> on Monday. 
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)&nbsp;</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)&nbsp;</li>
<li>B. Riley Financial, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>)&nbsp;</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)&nbsp;</li>
<li>NuScale Power Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>)&nbsp;</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>)&nbsp;</li>
<li>Curaleaf Hldgs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>)&nbsp;</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>)&nbsp;</li>
<li>Emergent BioSolutions Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)&nbsp;</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)&nbsp;</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>)&nbsp;</li>
</ul>
Companies reporting after Tuesday's closing bell include:&nbsp;
<ul>
<li>ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>)</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) </li>
<li>Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) </li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) </li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) </li>
<li>Sociedad Quimica y Minera S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) </li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) </li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) </li>
</ul>
Read Next:<a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

ASTS

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

DAVE

GTLB

OKTA

RILY

Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNT

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AOMR

ATNI

ATRO

CDXC

CGEN

CPIX

CRCT

CRDO

CTOS

CXDO

CYRX

EOLS

EOSE

ESPR

EVGO

FSTR

FTEK

GENI

GIFI

HGTY

HRZN

INFU

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

SCOR

SLND

SOPH

STIM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

<h3>Gainers</h3>
<ul>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock moved upwards by 35.2% to $0.8 during Thursday's pre-market session. The market value of their outstanding shares is at $6.5 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares rose 25.92% to $0.17. The company's market cap stands at $1.1 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares moved upwards by 23.52% to $12.81. The market value of their outstanding shares is at $38.9 million. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) stock rose 23.15% to $2.5. The market value of their outstanding shares is at $102.1 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares moved upwards by 17.54% to $1.34. The market value of their outstanding shares is at $3.6 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares moved upwards by 15.2% to $2.5. The company's market cap stands at $130.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock declined by 8.4% to $0.24 during Thursday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock declined by 7.62% to $20.15. The market value of their outstanding shares is at $354.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares fell 7.42% to $0.59. The company's market cap stands at $30.2 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares declined by 7.04% to $2.51. The company's market cap stands at $15.1 million. </li>
<li>Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) stock declined by 6.62% to $13.7. The market value of their outstanding shares is at $947.5 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 6.43% to $6.99. The market value of their outstanding shares is at $75.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

CHRO

ELTX

ERNA

HEPA

QNRX

TNFA

VIGL

XCUR

ZYME

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Biotech

Rigel Enrolls First Patient In Phase 1 Study Evaluating Fostamatinib In Sickle Cell Disease

<ul>
<li>Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE&#xAE; net product sales of $31.0 million, REZLIDHIA&#xAE; net product sales of $7.4 million and GAVRETO&#xAE; net product sales of $8.1 million</li>
<li>R289 granted Orphan Drug designation by the FDA for the treatment of MDS</li>
<li>Rigel anticipates 2025 total revenue of approximately $200 to $210 million</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2025.

Rigel Reports Q4 2024 Revenue Of $57.6M With TAVALISSE $31M, REZLIDHIA $7.4M, GAVRETO $8.1M; R289 Receives FDA Orphan Drug Status For MDS; 2025 Revenue Projected At $200M-$210M

R289 was previously granted&nbsp;Fast Track designation by the FDA for the treatment of patients with previously-treated transfusion dependent lower-risk MDS.

Rigel Pharmaceuticals Says FDA Granted Orphan Drug Designation To R289 For Treatment Of Myelodysplastic Syndromes

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 200 points on Tuesday.
The Dow traded up 0.53% to 43,132.84 while the NASDAQ climbed 1.05% to 19,972.38. The S&amp;P 500 also rose, gaining, 0.78% to 6,020.96.
Check This Out: <a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.8% on Tuesday.
In trading on Tuesday, health care shares rose by just 0.1%.
Top Headline
The composite manufacturing index in the U.S. Fifth District increased to -10 in December compared to a reading of -14 in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) shares shot up 13% to $7.00 after Waterous Energy Fund acquired 9,311,424 common shares and 2,654,179 common share purchase warrants of the company.</li>
<li>Shares of Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>)got a boost, surging 103% to $7.87 after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares were also up, gaining 73% to $5.91 after the company announced it launched &#8220;Ava&#8221; an agentic AI model for private jet booking.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Canoo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) shares dropped 8% to $1.4606.</li>
<li>Shares of Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) were down 8% to $24.80 after reporting fourth-quarter results.</li>
<li>Rigel Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) was down, falling 7% to $16.00.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $70.28 while gold traded up 0.1% at $2,630.20.
Silver traded up 0.1% to $30.205 on Monday, while copper rose 0.6% to $4.1085.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.17%, Germany's DAX fell 0.18% and France's CAC 40 rose 0.14%. Spain's IBEX 35 Index rose 0.33%, while London's FTSE 100 rose 0.42%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.32%, Hong Kong's Hang Seng Index gaining 1.08%, China's Shanghai Composite Index gaining 1.26% and India's BSE Sensex falling 0.09%.
Economics
<ul>
<li>U.S. Redbook index increased 5.9% year-over-year in the latest week, following a prior reading of 4.8% gain.</li>
<li>The composite manufacturing index in the U.S. Fifth District increased to -10 in December compared to a reading of -14 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669068/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Trading Ideas

CREV

GOEV

JTAI

LMNR

Dow Jumps Over 200 Points, Crude Oil Gains 1.5%

Rigel Pharmaceuticals shares are trading lower after B. Riley Securities cut its price target on the stock from $27 to $20.

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $15 to $25.

Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $25

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and lowers the price target from $27 to $20.

B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Lowers Price Target to $20

<ul>
<li>R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients</li>
<li>RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial&nbsp;data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being&nbsp;presented today by Dr. Guillermo Garcia-Manero (Poster #: 4595) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, in San Diego, California and virtually.&nbsp;

Rigel Pharmaceuticals Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated LR-MDS Patients

Press Releases

Rigel to Present at the Jefferies London Healthcare Conference

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel Provides Business Update and 2025 Outlook

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Comments

Rigel Pharmaceuticals

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL